Vaccines are one of the most effective tools we have for protecting our health. They have a long track record of safety and efficacy and savings across the health system, and are responsible for significant improvements in public health, including the eradication of smallpox and the near elimination of diseases like polio and measles.
Now a new report from the World Health Organization (WHO) puts a spotlight on yet another downstream benefit of vaccines – their ability to lower antibiotic use, decrease resources spent treating resistant infections and reduce the global burden of antimicrobial resistance (AMR). Data show:
- Vaccines targeting 23 pathogens could reduce the number of antibiotics needed by 22% every year. People who are vaccinated tend to stay healthier and out of the hospital, preventing secondary infections that may need antimicrobial medicines.
- Existing vaccines for pneumococcal pneumonia, Haemophilus influenzae type B and typhoid could avert up to 106,000 deaths associated with AMR each year. An additional 543,000 AMR-linked deaths could be prevented annually if vaccines in development for tuberculosis and Klebsiella pneumoniae are ultimately successful in reaching approval and rolled out globally to patients.
Increasing vaccine uptake can also drive substantial savings for the health care system – globally and here in the U.S.
- According to the same WHO report, the global hospital costs of treating resistant pathogens are estimated at $730 billion each year. Vaccines, if rolled out for all 23 evaluated pathogens in the WHO research, could save one-third of the hospital costs associated with AMR.
- The U.S. Centers for Disease Control and Prevention (CDC) estimates that over the last 30 years in the United States, childhood vaccines have saved nearly $2.2 trillion in health care related costs.
- Vaccines can reduce the risk and severity of vaccine-preventable diseases like flu, pneumococcal disease, shingles and whooping cough, which cost $27 billion in direct and indirect costs each year among adults over the age of 50.
Absent intervention, AMR could result in 39 million deaths between now and 2050, according to The Lancet. But thanks to the U.S. biopharmaceutical industry’s leading efforts to research and develop innovative vaccine technology, these powerful tools are protecting Americans and people around the globe from disease and helping mitigate the threat of long-term public health challenges like AMR.
Learn more about AMR here.
Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Andrew Powaleny
Why smart vaccine policy matters
New study: HPV vaccination helps prevent cervical cancer deaths
New research reinforces the importance of hepatitis B vaccination at birth
World Immunization Week: Putting preventable diseases in the past
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
New study: Measles setbacks harm health and America’s economy
Why the hepatitis B vaccine matters
Vaccines and autism: Decades of scientific evidence find no link
Why the vaccine injury program matters
Recognizing the importance of vaccination for American health and security
Answering common questions on mRNA technology
What to know about vaccine ingredients: Aluminum and thimerosal
World Immunization Week: Highlighting the importance of vaccines for public health
What you need to know: Measles and the MMR vaccine
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
The Patient Perspective: Vaccines
Addressing the mounting threat of antimicrobial resistance
How to protect your children’s health this school year
New Report: Vaccines continue to drive improved health outcomes
Showcasing the promise of biopharma at ASCO 2024
World Vaccine Congress: Building on vaccine success
A conversation with Sepsis Alliance President and CEO Thomas Heymann as World AMR Awareness Week kicks off
WHO Pandemic Agreement offers opportunities and risks for American innovators
New Report: 1,600 cancer treatments and vaccines in clinical development
What you should know about protecting your health this fall
Word of the Month: AMR
Key considerations as Congress works towards PAHPA reauthorization
A conversation with Dr. Mike Ybarra on the current state of COVID-19
Policies need to address the growing threat of antimicrobial resistance
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
What we’ve learned from three years of fighting COVID-19
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
What they are saying: PASTEUR Act can help fight antimicrobial resistance
Word of the Month: What is TRIPS?
What you should know about RSV
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Global COVID-19 vaccination matters now and for the future
Preventing the next public health emergency: New evidence demonstrates need to address antimicrobial resistance
Understanding breakthrough COVID-19 infections
The important role of antivirals in the fight against COVID-19
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
Americans 12 years of age and older are eligible for COVID-19 vaccines
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
Patient safety is at the heart of COVID-19 vaccine R&D
Data shows that Americans are relying on vaccines to get us through the pandemic
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
The next threat: Combatting antimicrobial resistance
Growing trend: Increased vaccine confidence
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Understanding the emergency use authorization process for COVID-19 vaccines
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Supporting access to vaccines for Part D beneficiaries
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Why vaccines work in the fight against measles and other infectious diseases
Medicare Monday: Helping beneficiaries access vaccines
New report and event examine the new era of vaccines
Medicare Monday: Strengthening access to vaccines for seniors
Leveraging the power of vaccines to prevent antimicrobial resistance
Antimicrobial Resistance
Vaccines
Leveraging the power of vaccines to prevent antimicrobial resistance
Leveraging the power of vaccines to prevent antimicrobial resistance